Business
OWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB ("Helsinki") Committee
OWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB ("Helsinki") Committee.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB (\"Helsinki\") Committee\n\n\n\n\n\nOWC Pharmaceutical Research Corp to Submit Psoriasis Topical Cream IRB Safety Protocol to the Israeli National IRB (\"Helsinki\") Committee\nFinal IRB (\"Institutional Review Board\") for safety study\nPR Newswire\nPETACH TIKVA, Israel, November 15, 2016\n\n\n\nPETACH TIKVA, Israel, November 15, 2016 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWCP\" or the \"Company\"), thorough its Israeli based fully owned subsidiary, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is submitting the final Psoriasis IRB safety protocol for the Israeli national IRB committee at the Health Minister office.\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )\n\n\n     (Photo: http://photos.prnewswire.com/prnh/20161115/439488 )\n\n\nThe IRB protocol was first approved by the hospital which will perform the safety study and after obtaining its approval the IRB protocol is being submitted for approval to the national IRB committee. The national IRB committee is scheduled to ensemble at the beginning of December 2016.\n\nUpon the expected approval of the safety protocol by the national committee, the company will immediately engage with the study which will last approximately 12 weeks.\n\nResults are expected by the end of March 2016 and upon reaching satisfactory results the company intends to start production, marketing and sales in the US and EU in parallel to local IL efforts.\n\nThe Safety study is designed to test multiple escalating doses to determine the safety and tolerability of the medical grade cannabis cream on healthy volunteers. The psoriasis topical crème infused with active cannabinoids is a unique delivery-system product of OWC designed to be used for skin diseases, where the first application will be tested for safety and efficacy for Psoriasis. The efficacy studies have already been started and results are expected by the end of Jan 2017.\n\nPsoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, ...